Fludarabine, mitoxantrone and dexametasone in the treatment of relapsed and refractory low-grade non-Hodgkin lymphoma.

被引：0
|
作者：
Sawczuk-Chabin, J
Kalinka, E
Centkowski, P
Budziszewska, K
Ceglarek, B
Najda, J
Blasinska-Morawiec, M
Sulek, K
Holowiecki, J
Konopka, L
Warzocha, K
机构：
[1] Inst Hematol & Blood Transfus, Dept Hematol, Warsaw, Poland
[2] Reg Canc Ctr, Dept Proliferat Dis, Lodz, Poland
[3] Mil Inst Med, Dept Hematol, Warsaw, Poland
[4] Inst Hematol & Blood Transfus, Dept Hematol & Internal Med, Warsaw, Poland
[5] L Warynski Silesian Med Acad, Dept Hematol, Katowice, Poland
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.4738.4738
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4738
引用
收藏
页码：265B / 265B
页数：1
相关论文
共 50 条
  • [41] Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma
    Misgeld, E
    Germing, U
    Aul, C
    Gattermann, N
    LEUKEMIA RESEARCH, 2001, 25 (01) : 95 - 98
  • [42] Randomized phase II evaluation of fludarabine (RdA) and 2-chloredeossiadenosine (CdA) in the treatment of relapsed/refractory low-grade non-Hodgkin's lymphoma (NHL) and CLL.
    Tondini, C
    Balzarotti, M
    Rampinelli, I
    Luoni, M
    DePaoli, A
    Valagussa, P
    Santoro, A
    Bajetta, E
    Bonadonna, G
    Bregni, M
    BLOOD, 1997, 90 (10) : 1532 - 1532
  • [43] Etoposide, mitoxantrone and prednisone, a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma
    Doorduijn, JK
    Spruit, PH
    Van der Holt, B
    Van't Veer, MB
    Budel, LM
    Löwenberg, B
    Sonneveld, P
    HAEMATOLOGICA, 2000, 85 (08) : 814 - 819
  • [44] Bexxar®:: Novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma
    Vose, JM
    ONCOLOGIST, 2004, 9 (02): : 160 - 172
  • [45] Concurrent chemotherapy and radiotherapy (CRT) in relapsed or refractory non-Hodgkin's lymphoma.
    Lapusan, S
    Ribrag, V
    Driss, B
    Vantelon, SM
    Fermé, C
    Bourhis, JH
    Girinsky, T
    BLOOD, 2001, 98 (11) : 243B - 244B
  • [46] Allogenic bone marrow transplantation for refractory and recurrent low grade non-Hodgkin's lymphoma.
    Molina, L
    Nicolini, F
    Viret, F
    PegourieBandelier, B
    Leger, J
    Sotto, JJ
    BLOOD, 1995, 86 (10) : 823 - 823
  • [47] Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: Promising results in marginal zone lymphoma
    Economopoulos, Theofanis
    Psyrri, Amanda
    Fountzilas, George
    Tsatalas, Constantinos
    Anagnostopoulos, Athanasios
    Papageorgiou, Sotirios
    Xiros, Nikolaos
    Dimopoulos, Meletios Athanasios
    LEUKEMIA & LYMPHOMA, 2008, 49 (01) : 68 - 74
  • [48] Fludarabine and mitoxantrone for the refractory relapse treatment of B-cell low-grade non-Hodgkin lymphoma (NHL):: LACOHG first interim report (Latin American Cooperative Oncology Hematology Group).
    Baltazar-Arellano, Severiano
    Pimentel, Patricia
    Vera, Luis
    Bezares, Fernando
    Malaga, Jose
    Huamani-Z, Julia
    Montante, Antonio
    Rivas-Vera, Silvia
    Carrasco-Yalan, Antonio A.
    Beltran-Garate, Brady E.
    BLOOD, 2006, 108 (11) : 247B - 248B
  • [49] TRANSFORMATION OF LOW-GRADE TO HIGH-GRADE NON-HODGKIN LYMPHOMA
    HERAIT, P
    AUDOUIN, J
    RIO, B
    ZYLBERAIT, D
    MARIE, JP
    DIEBOLD, J
    ZITTOUN, R
    ANNALES DE MEDECINE INTERNE, 1986, 137 (04): : 342 - 345
  • [50] Historical perspective on the treatment challenges of low-grade non-Hodgkin's lymphoma
    Cabanillas, Fernando
    SEMINARS IN HEMATOLOGY, 2007, 44 (03) : S2 - S6
12345